Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

June 4, 2011 By Bio-Medicine.Org

SAN DIEGO, June 4, 2011 /PRNewswire/ — Amylin Pharmaceuticals,
Inc. (Nasdaq:
AMLN) today announced results from a study that showed
treatment with metreleptin, an investigational treatment that is an
analog of the human hormone leptin, improved diabetes and lipid
control in patients with partial lipodystrophy. Data from this
study, the first findings from patients receiving metreleptin
through Amylin’s lipodystrophy expanded access program, were
presented at the 93rd Annual Meeting and Expo of The Endocrine
Society (ENDO) in Boston.

In this study, being conducted under a treatment IND authorized
by the U.S. Food and Drug Administration (FDA), metreleptin is made
available to patients with rare forms of lipodystrophy who have one
or more metabolic abnormalities, including diabetes and
hypertriglyceridemia (high levels of triglycerides in the
bloodstream). This analysis focused on patients with partial
lipodystrophy who had received treatment for at least six months.
Treatment with metreleptin resulted in improvements from baseline
in A1C (a measure of average blood sugar over three months) and
triglycerides. Further, the majority of patients receiving
metreleptin were able to reduce or discontinue treatment with
pre-existing diabetes medications, including insulin.  

“We are committed to assisting patients who are living with
lipodystrophy, a chronic and often debilitating disease that is not
adequately managed by existing therapies,” said Christian Weyer,
M.D., senior vice president, research and development, Amylin
Pharmaceuticals. “Our expanded access program enables us to provide
patients with metreleptin while we continue working with the FDA to
make the medicine more broadly available to patients with this rare
disorder.”

Results of this analysis were presented by Suma Amarnath, M.D.,
a member of the research team led by Elif Oral, M.D. during an
or

‘/>”/>

SOURCE

Related Articles Read More >

An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
How Abbott developed the first-of-its-kind Infinity DBS system
Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
Q&A with Darshin Patel, who led the Edwards Lifesciences Sapien M3 TMVR system’s development
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe